Beyond efficacy and safetythe need for convenient and cost-effective iron therapy in health care

NDT Plus

Volumn 4, Issue SUPPL. 1, 2011, Pages

  Bhandari, Sunil ^a  

^a HULL AND EAST YORKSHIRE HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

anaemia; chronic kidney disease; cost; ferumoxytol (Feraheme); iron carboxymaltose (Ferinject); iron isomaltoside 1000 (Monofer); iron sucrose (Venofer); low molecular weight iron dextran (Cosmofer); patient choice

Indexed keywords

FERELECIT; FERRIC CARBOXYMALTOSE; FERRIC HYDROXIDE SUCROSE; FERROUS GLUCONATE; FERUMOXYTOL; HEPCIDIN; IRON; IRON DEXTRAN; IRON ISOMALTOSIDE 1000; MONOFER; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; UNCLASSIFIED DRUG;

ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; COMPLEX FORMATION; COST EFFECTIVENESS ANALYSIS; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; GLOMERULUS FILTRATION RATE; HUMAN; IRON ABSORPTION; IRON DEFICIENCY; IRON METABOLISM; IRON OVERLOAD; IRON THERAPY; KIDNEY FUNCTION; LIPID PEROXIDATION; LOW DRUG DOSE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; REPEATED DRUG DOSE; SIDE EFFECT; SINGLE DRUG DOSE;

EID: 79958016700     PISSN: 17530784     EISSN: 17530792     Source Type: Journal    
DOI: 10.1093/ndtplus/sfr044     Document Type: Article

References (50)

1. Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32: 112-119
2. Besarab A et al. Optimization of epoietin therapy with intravenous iron therapy in haemodialysis patient. J Am Soc Nephrol 2000; 11: 530-538 (Pubitemid 30115083)
3. Hsu C, McCulloch CE, Curhan GC. Epidemiology of anaemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 2002; 13: 504-510 (Pubitemid 34106294)
4. Health D. The National Service Framework for Renal Service (Part 2, Chronic Kidney Disease) 2005: London
5. Locatelli F et al. Revised European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 20041-47
6. Bhandari S, Brownjohn A, Turney J. Effective utilization of erythropoietin with intravenous iron therapy. J Clin Pharm Ther 1998; 23: 73-78 (Pubitemid 28380378)
7. Valderrabano F et al. Pre-dialysis survey on anaemia management (PRESAM). Nephrol Dial Transplant 2003; 18: 89-100 (Pubitemid 36104483)
8. Drueke T et al. Normalisation of haemoglobin level in patients with chronic kidney disease and anaemia. N Engl J Med 2006; 355: 2017-2084
9. Pfeffern M et al. A trial of darbepoetin in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-2032
10. Singh A et al. Correction of anaemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098 (Pubitemid 44749317)
11. Guidelines N. Anaemia management in people with chronic kidney disease (CKD). Clinical Guidance. London: Royal College of Physicians, 2006; 1-172
12. Agarwal R. Nonhematological benefits of iron. Am J Nephrol 2007; 27: 565-571 (Pubitemid 350014943)
13. Bhandari S, Brownjohn AM, Turney JH. Response of mean reticulocyte haemoglobin content to intravenous iron therapy in haemodialysis patients. Nephrol Dial Transplant 1998; 13: 3276-3277 (Pubitemid 28534759)
14. Macdougall I, Tucker B, Thompson J. A randomized controlled study of iron supplementation in patients with erythropoietin. Kidney Int 1996; 50: 1694-1699 (Pubitemid 26364277)
15. Ganz T. Molecular control of iron transport. J Am Soc Nephrol 2007; 18: 394-400 (Pubitemid 46193304)
16. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003; 102: 783-788 (Pubitemid 36917762)
17. Mircescu G et al. Intravenous iron supplementation for the treatment of anaemia in pre-dialyzed chronic renal failure patients. Nephrol Dial Transplant 2006; 21: 120-124 (Pubitemid 43057119)
18. Rozen-ZviB et al. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis. Am J Kidney Dis 2008; 52: 897-906
19. Heath C, Strauss M, Castle W. Quantitative aspects of iron deficiency in hypochronic anaemia. J Clin Invest 1932; 1: 1293-1312
20. Goetsch A, Moore C, Minnich V. Observations on the effects of massive doses of iron given intravenously to patients with hyperchromic anemia. Blood 1946; 1: 129-142
21. Nissim J. Intravenous administration of iron. Lancet 1947; 2: 49-51
22. Baird I, Podmore D. Intra-muscular iron therapy in iron deficiency anemia. Lancet 1954; 2: 942-946
23. Auerbach M, Winchester J, Wahab A. A randomized trial of three iron dextran infusion methods for anaemia in EPO-treated dialysis patients. Am J Kidney Dis 1998; 31: 81-86 (Pubitemid 28116687)
24. Moniem K, Bhandari S. Tolerability and efficacy of parenteral iron therapy in haemodialysis patients a comparison of two preparations. Transfus Altern Transfus Med 2007; 9: 37-42
25. Pharmaceuticals V. Cosmofer summary of product characteristics 2001
26. Halliwell B, Gutteridge J. Role of free radicals and catalytic metal ions in human disease: an overview. Meth Enzymol 1990; 186: 1-85 (Pubitemid 20279941)
27. Zager R et al. Parenteral iron formulations: a comparative toxicological analysis and mechanisms of cell injury. Am J Kidney Dis 2002; 40: 90-103 (Pubitemid 34701216)
28. Carlini RG et al. Apoptotic stress pathway activation mediated by iron on endothelial cells in vitro. Nephrol Dial Transplant 2006; 21: 3055-3061 (Pubitemid 44574155)
29. Zager R, Johnson A,Hanson S. Parenteral iron nephrotoxicity, potential mechanisms and consequences. Kidney Int 2004; 66: 114-156
30. Agarwal R et al. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 2004; 65: 2279-2289 (Pubitemid 38670014)
31. Shah S et al. Oxidants in chronic kidney disease. J Am Soc Nephrol 2007; 18: 16-28 (Pubitemid 46053418)
32. Bhandari S, Naudeer S. Improving efficiency and value in health care. Intravenous iron management for anaemia associated with chronic kidney disease: linking treatment to an outpatient clinic, optimizing service provision and patient choice. J Eval Clin Pract 2008; 14: 996-1001
33. Ankers SD et al. FAIR-HF Trial: ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009; 361: 3426-2448
34. Wikström B et al. Monofer® (iron isomaltoside 1000), a novel intravenous iron for treatment of iron deficiency in chronic kidney disease (CKD) patients. J Nephrol 2011 In press
35. Zheng S. Iron deficiency anemia and iron losses after renal transplantation. Transpl Int 2009; 22: 434-440
36. Bolger A. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol 2006; 48: 1225-1227 (Pubitemid 44345150)
37. Kulnigg S et al. A novel intravenous iron treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol 2008; 103: 1182-1192 (Pubitemid 351677967)
38. Munoz M, Gomez-Ramirez S, Garcia-Erce J. Intravenous iron in inflammatory bowel disease. World J Gastroenterol 2009; 15: 4666-4674
39. WyckDVet al. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion 2009; 49: 2719-2728
40. Seid M et al. Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial. AmJ Obstet Gynecol 2008; 199: 435-437
41. Auerbach M, Ballard H, T. JR. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 2004; 22: 1301-1307 (Pubitemid 41079845)
42. Gasche C et al. Iron, anaemia, and inflammatory bowel diseases. Gut 2004; 53: 1190-1197 (Pubitemid 38961976)
43. Tagboto S et al. The efficacy of a single dose if intravenous ferric carboxymaltose (FERINJECT(r)) on anaemia in a pre-dialysis population of CKD patients. J Ren Care 2009; 35: 18-23
44. Covic A, Mircescu G. The safety and efficacy of intravenous ferric carboxymaltose in anaemic patients undergoing haemodialysis: a multi-centre, open-label, clinical study. Nephrol Dial Transplant 2010; 25: 2722-2730
45. Landry R et al. Pharmacokinetic study of ferumoxytol: a new iron replacement therapy in normal subjects and hemodialysis patients. Am J Nephrol 2005; 25: 400-410 (Pubitemid 41160999)
46. Singh A et al. Safety of ferumoxytol in patients with anemia and CKD. Am J Kidney Dis 2008; 52: 907-915
47. Spinowitz BS et al. Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc Nephrol 2008; 19: 1599-1605
48. (SPC), F.-S.o.P.C. Ferinject-summary of product characteristics (SPC) 2001
49. A/S, P. 2010Monofer Core SPC, data on file
50. Sinha S, Chiu D, Peebles G et al. Accelerated total dose infusion of low molecular weight iron destran is safe and efficacious in chronic kidney disease patients. Q J Med 2011; 104: 221-230